Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0009952 (febrile convulsions)
 1,215 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A pharmacokinetic study of sodium valproate (DPA) was undertaken in children treated with this drug after a febrile convulsion. In infants, after a single oral dose of 20 mg/kg body weight in the first morning meal, plasma kinetic data were as follows: T max 2.4 hr +/- 1.1; total DPA maximum plasma concentration: 94 micrograms/ml +/- 28; T 1/2: 12.4 hr +/- 4.9; the distribution volume was 0.25 l/kg +2- 0.07 and plasma clearance was 0.014 l/kg/hr +2- 0.004. Control of prolonged treatment showed that the measured plasma concentrations were not correlated with the daily dosage. Furthermore, when febrile convulsions are concerned, one should carefully weight the recently reported hepatic toxicity of DPA, against the usually good prognosis of febrile convulsions.
 ...
PMID:[Pharmacokinetic elements of sodium valproate. Use in febrile convulsions in children]. 640 54

In 47 children followed for 1 year after the first "simple" febrile convulsion, dipropylacetate (Depakine, 20 mg/kg) was as effective in preventing new febrile convulsions (a single recurrence in 4% of 47 children) as was phenobarbital (5 mg/kg) or primidone (25 mg/kg) (a single recurrence in 4% of 47 children), and there were no side effects. Of 47 untreated children followed for 1 year, 55% had 1 to 4 new febrile convulsions. All medications were given in divided doses morning and evening.
 ...
PMID:Prevention of febrile convulsions with dipropylacetate (Depakine). 989 Jul 91